Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02068989 · ClinicalTrials.gov registry record
Study of Stress Hyperglycemia as an Indicator of Diabetes Mellitus
A clinical trial, sponsored by Yale University.
- Terminated
- Registry status
- 1
- Enrollment target
NCT02068989: Clinical Trial study, sponsored by Yale University.
NCT02068989 is a clinical trial that was terminated before completion, run by Yale University. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02068989 was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
We hypothesize that stress hyperglycemia is an indicator that a patient will develop type 2 diabetes mellitus in the future. Subjects who are not diabetic are enrolled and blood glucose readings reviewed during their intensive care unit stay. All subjects are consented and have a HbA1C level drawn to determine if they have diabetes mellitus or not. They are then followed up in 1 year and the HbA1C repeated to determine if they have developed diabetes mellitus over the course.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2013-02 |
| Est. Completion | 2015-03 |
Why NCT02068989 stopped before completion
NCT02068989 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02068989 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02068989 about?
NCT02068989 is a clinical study titled "Study of Stress Hyperglycemia as an Indicator of Diabetes Mellitus". We hypothesize that stress hyperglycemia is an indicator that a patient will develop type 2 diabetes mellitus in the future. Subjects who are not diabetic are enrolled and blood glucose readings reviewed during their intensive care unit stay. All subjects are consented and have a HbA1C level drawn t...
What is the current status of trial NCT02068989?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2013-02. Estimated completion is 2015-03.
Who is sponsoring clinical trial NCT02068989?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia